Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
Response to Mittal and Sharma Letter to the Editor.
À¶Ý®ÊÓƵ
Response to Mittal and Sharma Letter to the Editor. Arthritis & rheumatology (Hoboken, N.J.) Spiera, R., Chung, L., Frech, T., Domsic, R., Hsu, V., Furst, D., Simms, R., Mayes, M., Martyanov, V., Whitfield, M., Dgetluck, N., Dinh, Q., White, B. 2020Abstract
On behalf of the authors, we appreciate the interest from Mittal and Sharma in the Phase 2 study results of lenabasum for the treatment of diffuse cutaneous systemic sclerosis (dcSSc) [1]. The small sample size and specified set of efficacy analyses done in this study preclude separate subset analyses of the course of interstitial lung disease, pulmonary artery hypertension, gastrointestinal involvement, or all efficacy analyses by disease duration or background immunosuppressant use, over 16 weeks.
View details for
View details for